CHEN-HUA LIUDING-SHINN CHENJIA-HORNG KAO2021-09-042021-09-0420070028-4793https://www.scopus.com/inward/record.uri?eid=2-s2.0-35348953102&partnerID=40&md5=78aa34f17e0384f4f1fbbe2aeac3af9bhttps://scholars.lib.ntu.edu.tw/handle/123456789/582155[SDGs]SDG3peginterferon alpha2a; ribavirin; genotype; hepatitis C; Hepatitis C virus; human; letter; priority journal; recurrence risk; statistical significance; treatment duration; virotherapy; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon Alfa-2a; Polyethylene Glycols; Recurrence; Ribavirin; Viral Loadletter179483452-s2.0-35348953102